Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Analysis of Mutant cMPL in Philadelphia Chromosome-Negative Myeloproliferative Disorders (Ph − MPDs) Using a Novel High-Sensitivity Assay.

Scott J. Samuelson, MD, Sabina Swierczek, Ph.D., Charles J. Parker, M.D., Kenneth Boucher, Ph.D., Jaroslav Jelinek, M.D., Josef Prchal, M.D.

Blood (2007) 110 (11): 2544.

https://doi.org/10.1182/blood.V110.11.2544.2544

Published: 2007

Journal Articles

Hypomethylation Induction and Molecular Response after Decitabine Therapy in Chronic Myelomonocytic Leukemia (CMML).

Yasuhiro Oki, MD, Jaroslav Jelinek, M.D. Ph.D., Hagop M. Kantarjian, M.D., Jean-Pierre J. Issa, M.D.

Blood (2006) 108 (11): 2322.

https://doi.org/10.1182/blood.V108.11.2322.2322

Published: 2006

Journal Articles

Comprehensive Promoter Methylation Analysis of Genes on 5q31.1 in MDS and AML.

Yasuhiro Oki, MD, Jaroslav Jelinek, M.D, PhD, Lanlan Shen, M.D, PhD, Jean-Pierre Issa, MD

Blood (2005) 106 (11): 3443.

https://doi.org/10.1182/blood.V106.11.3443.3443

Published: 2005

Journal Articles

Epigenetic Suppression of the CTNNA1 Gene, Encoding the α-Catenin Protein, which Is Located in the 5q31 Critical Deleted Region in Malignant Myeloid Disorders with del(5q).

Ting Xi Liu, M.D., Ph.D., Michael Becker, M.D., Karl Hsu, M.D., Jaroslav Jelinek, M.D., Ph.D., Min Deng, M.D., Clara Bloomfield, M.D.4, Jean-Pierre Issa, M.D., Michael F. Clarke, M.D., A. Thomas Look, M.D.4

Blood (2004) 104 (11): 203.

https://doi.org/10.1182/blood.V104.11.203.203

Published: 2004

Journal Articles

Hypomethylation Dynamics Following Decitabine Therapy in Chronic Myelogenous Leukemia.

Jean-Pierre J. Issa, M.D., Vazganush Gharibyan, Ph.D., Jaroslav Jelinek, M.D., Ph.D., Gail Morris, RN, Srdan Verstovsek, M.D., Moshe Talpaz, M.D., Guillermo Garcia-Manero, M.D., Hagop M. Kantarjian, M.D.

Blood (2004) 104 (11): 2956.

https://doi.org/10.1182/blood.V104.11.2956.2956

Published: 2004

Journal Articles

Identification of 41 Novel Promoter-Associated CpG Islands Methylated in Leukemias.

Jaroslav Jelinek, M.D., Ph.D., Rajan Mannari, M.D., Jean-Pierre Issa, M.D.

Blood (2004) 104 (11): 1126.

https://doi.org/10.1182/blood.V104.11.1126.1126

Published: 2004

NARROW

Analysis of Mutant cMPL in Philadelphia Chromosome-Negative Myeloproliferative Disorders (Ph − MPDs) Using a Novel High-Sensitivity Assay.

Hypomethylation Induction and Molecular Response after Decitabine Therapy in Chronic Myelomonocytic Leukemia (CMML).

Comprehensive Promoter Methylation Analysis of Genes on 5q31.1 in MDS and AML.

Epigenetic Suppression of the CTNNA1 Gene, Encoding the α-Catenin Protein, which Is Located in the 5q31 Critical Deleted Region in Malignant Myeloid Disorders with del(5q).

Hypomethylation Dynamics Following Decitabine Therapy in Chronic Myelogenous Leukemia.

Identification of 41 Novel Promoter-Associated CpG Islands Methylated in Leukemias.

Email alerts

ASH Publications

American Society of Hematology

Analysis of Mutant cMPL in Philadelphia Chromosome-Negative Myeloproliferative Disorders (Ph − MPDs) Using a Novel High-Sensitivity Assay.

Hypomethylation Induction and Molecular Response after Decitabine Therapy in Chronic Myelomonocytic Leukemia (CMML).

Comprehensive Promoter Methylation Analysis of Genes on 5q31.1 in MDS and AML.

Epigenetic Suppression of the CTNNA1 Gene, Encoding the α-Catenin Protein, which Is Located in the 5q31 Critical Deleted Region in Malignant Myeloid Disorders with del(5q).

Hypomethylation Dynamics Following Decitabine Therapy in Chronic Myelogenous Leukemia.

Identification of 41 Novel Promoter-Associated CpG Islands Methylated in Leukemias.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only